3,410 Shares in Unum Group (NYSE:UNM) Acquired by Montag A & Associates Inc.

Montag A & Associates Inc. acquired a new stake in shares of Unum Group (NYSE:UNM) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,410 shares of the financial services provider’s stock, valued at approximately $249,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Unum Group by 1.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 5,500,508 shares of the financial services provider’s stock worth $326,950,000 after buying an additional 55,014 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Unum Group by 50.0% in the 3rd quarter. Franklin Resources Inc. now owns 469,342 shares of the financial services provider’s stock valued at $29,554,000 after purchasing an additional 156,380 shares in the last quarter. Blue Trust Inc. increased its position in Unum Group by 44.1% during the 4th quarter. Blue Trust Inc. now owns 16,495 shares of the financial services provider’s stock worth $1,205,000 after purchasing an additional 5,047 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in Unum Group by 89.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 111,831 shares of the financial services provider’s stock valued at $6,647,000 after purchasing an additional 52,813 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC acquired a new stake in Unum Group in the third quarter valued at approximately $1,074,000. 86.57% of the stock is currently owned by institutional investors.

Insider Transactions at Unum Group

In other news, CEO Richard P. Mckenney sold 58,865 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $75.39, for a total transaction of $4,437,832.35. Following the transaction, the chief executive officer now owns 1,007,003 shares of the company’s stock, valued at $75,917,956.17. This represents a 5.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Lisa G. Iglesias sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $72.61, for a total value of $363,050.00. Following the completion of the sale, the executive vice president now directly owns 35,840 shares of the company’s stock, valued at $2,602,342.40. This trade represents a 12.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,865 shares of company stock valued at $6,315,082 in the last quarter. 0.93% of the stock is currently owned by company insiders.

Unum Group Price Performance

Shares of NYSE UNM opened at $74.42 on Tuesday. The company has a market capitalization of $13.59 billion, a PE ratio of 7.86, a P/E/G ratio of 1.17 and a beta of 0.80. The company has a quick ratio of 0.28, a current ratio of 0.29 and a debt-to-equity ratio of 0.32. Unum Group has a twelve month low of $48.28 and a twelve month high of $79.43. The firm has a fifty day simple moving average of $74.19 and a 200 day simple moving average of $66.35.

Unum Group (NYSE:UNM) last posted its quarterly earnings data on Tuesday, February 4th. The financial services provider reported $2.03 earnings per share for the quarter, missing the consensus estimate of $2.14 by ($0.11). Unum Group had a return on equity of 14.91% and a net margin of 13.81%. On average, sell-side analysts forecast that Unum Group will post 9.12 EPS for the current year.

Unum Group Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Friday, January 24th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date of this dividend was Friday, January 24th. Unum Group’s payout ratio is 17.74%.

Analysts Set New Price Targets

A number of research analysts have recently commented on UNM shares. Barclays increased their price target on Unum Group from $76.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, January 6th. Piper Sandler lifted their price target on Unum Group from $82.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Jefferies Financial Group upped their price objective on Unum Group from $91.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. Evercore ISI raised shares of Unum Group from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $67.00 to $84.00 in a report on Thursday, November 14th. Finally, Morgan Stanley raised their price target on shares of Unum Group from $62.00 to $64.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $80.33.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.